Headlines about Signal Genetics (NASDAQ:MGEN) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Signal Genetics earned a news sentiment score of 0.23 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 45.1051942583025 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of Signal Genetics (NASDAQ:MGEN) opened at 9.17 on Wednesday. The firm’s 50-day moving average is $10.91 and its 200 day moving average is $11.82. The stock’s market capitalization is $197.00 million. Signal Genetics has a 1-year low of $0.12 and a 1-year high of $18.00.
Signal Genetics (NASDAQ:MGEN) last posted its quarterly earnings results on Friday, August 11th. The medical research company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.13. The business had revenue of $0.72 million during the quarter, compared to analyst estimates of $0.46 million. Signal Genetics had a negative net margin of 770.31% and a negative return on equity of 92.62%. On average, analysts expect that Signal Genetics will post ($1.52) EPS for the current fiscal year.
A number of equities research analysts recently issued reports on MGEN shares. Zacks Investment Research downgraded shares of Signal Genetics from a “hold” rating to a “sell” rating in a report on Tuesday, May 16th. Cowen and Company started coverage on shares of Signal Genetics in a report on Thursday, June 1st. They issued an “outperform” rating for the company. ValuEngine upgraded shares of Signal Genetics from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. Chardan Capital restated a “buy” rating and issued a $26.00 target price on shares of Signal Genetics in a report on Tuesday, July 25th. Finally, Wedbush restated a “buy” rating on shares of Signal Genetics in a report on Friday, August 18th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $19.00.
Signal Genetics Company Profile
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Signal Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Signal Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.